Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Improved patient access to specialized medical care and increased use of target therapies in oncology are expanding the multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) markets in Brazil and Mexico. Moreover, recent approvals and upcoming marketing authorizations will strengthen the treatment armamentarium for these diseases and provide further therapy options. However, premium-priced agents for MM and NHL (such as Janssen’s Velcade) face differing degrees of coverage and use restrictions within and across each country. In addition, in the past two years, Brazil’s National Agency of Health Regulation ( Agência Nacional de Vigilância Sanitária , ANVISA) has denied approval of some agents for MM and NHL in Brazil, while in Mexico, others have received a conditional opinion from COFEPRIS’s New Molecules Committee. These market access hurdles showcase the increasingly rigorous regulatory and reimbursement environments in these countries.
Decision Resources Group’s Emerging Markets Physician & Payer Forum report “The Impact of LATAM (Brazil and Mexico) Payer Policy on Prescribing in Non-Hodgkin’s Lymphoma and Multiple Myeloma” surveys 100 oncologists and hematologists and interviews 7 payers in Brazil and Mexico to explore how payer policy influences prescribing of approved key therapies for MM and NHL, determine the factors that will promote or restrict uptake of new entrants, and assess how access to treatment will evolve in the next 2-3 years for these indications. Interviewed payers include the following:
- Brazil: Head of pharmaceutical division of Hospital das Clinicas (HC) and director of the pharmacy and therapeutics (P&T) committee; representative of HC pharmacy in the therapeutic committee of the Department of Health of the São Paulo state; head of central service of drug distribution and logistics at INCA (Instituto Nacional do Cancer); director of drug supply and relationship with service providers/budget controller of Unimed; pharmacist and supply manager of specialty drugs from SUS programs in HCFMUSP.
- Mexico: National coordinator of special programs in the division of hospital regulation from the medical department of ISSSTE; coordinator of the Nacional Guías de Práctica Clínica; CENETEC-Salud and internist M.D. from the IMSS at a second level healthcare hospital; oncologist KOL from the Instituto Mexicano de Investigación del Cancer and Instituto Nacional de Cancerologia (INCan) specialized in onco-hematology; former employee of COFEPRIS with regulatory affairs experience.